Changchun Institute of Biological Products Co., Ltd.
Establishment time : 1948
website : http://www.cibp.cncn.com/
Main Product : Vaccines, biological products
Company Profile
Changchun Institute of Biological Products Co., Ltd. is a renowned company established in 1948, specializing in the production of vaccines and biological products. With a large company size and a strong presence in both domestic and international markets, the company is a leading producer of vaccines in China and has a competitive edge in the global market. Visit their website for more information: http://www.cibp.cncn.com/
Changchun Zhuoyi Biological Co., Ltd
Company Profile
Changchun Zhuoyi Biological Co., Ltd., located in Shuangyang Economic Development Zone of Changchun City, is a key vaccine manufacturer invested by Zhejiang SelCorning Biotechnology Co., Ltd. in Jilin Province, and a vice chairman unit of Zhejiang Chamber of Commerce in Jilin Province. The company was founded on January 27, 2005. Mr. Feng Xingfu, chairman and general manager of the company, graduated from the Department of Biology, University of Science and Technology of China, and has been engaged in the marketing and enterprise management of biological products since the 1980s. The company has a registered capital of one hundred and one million six hundred and ninety-two thousand seven hundred and eighty-four yuan, covers an area of 41600 square meters, and has the leading vaccine research and development and production capacity in China. Changchun Zhuoyi Biological Co., Ltd. is a new vaccine manufacturer integrating R&D, production and sales. At present, the biological products approved by the company are mainly Rabies Vaccine (Vero cell) for Human Use, Freeze-dried. The company successfully passed the two in one inspection at the end of 2016 and obtained the registration approval and GMP certificate, which was officially put into production in January 2017. The company's existing production workshop covers an area of about 5700 square meters, with a cumulative investment of 400 million yuan. At present, the maximum annual output is 1 million people. The second phase workshop has been completed at the end of 2018, and will be officially produced in 2020. By then, the production capacity can reach 4 million people. The company has nearly 2000 square meters of pilot scale research workshop, advanced equipment such as bioreactor, ultrafiltration system, AKTA purification workstation, fluorescence microscope, etc., which are used for virus culture, improvement of purification system and identification of recombinant protein. The company has maintained close scientific research cooperation with many scientific research institutions at home and abroad. At present, the company is developing a serum rabies vaccine and a broad-spectrum human papillomavirus vaccine jointly developed with the Institute of Basic Medicine of the Chinese Academy of Medical Sciences. It is planned to cooperate with Murdoch Children's Research Institute in Australia to develop the round vaccine project. At the same time, the company also actively explores the path of internationalization. At present, the company has started to register in the Philippines, Pakistan, Cambodia, Bangladesh, Mongolia, Uzbekistan and other countries. It is estimated that the export of finished products in some markets will be realized by 2020. The company's technical cooperation project with Australia is one of the company's many international cooperation projects. The company always adheres to the concept of "standardized management, quality first", and adheres to the core values of "honesty, diligence, innovation, preciseness, learning and happiness", so as to provide high-quality vaccine products to serve the health of the people.
Jiangsu Province Centers for Disease Control and Prevention
Establishment time : 1963
website : http://www.jscdc.cn/
Main Product : Disease prevention and control services, public health research, emergency response
Company Profile
The Jiangsu Province Centers for Disease Control and Prevention is a government agency responsible for disease prevention and control, public health research, and emergency response in Jiangsu Province, China. Established in 1963, the center plays a crucial role in safeguarding the health of the local population and responding to public health emergencies. With a large team of experts and strong government support, the center is a leading provider of public health services in the region. Visit their website at http://www.jscdc.cn/ for more information.
Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
Establishment time : 1994
website : www.tianyuanbio.com
Main Product : Heparin Sodium, Enoxaparin Sodium, Hyaluronic Acid, etc.
Company Profile
Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. is a reputable company specializing in the production and distribution of bio-pharmaceutical products. Established in 1994, the company has grown to become a major player in the industry, offering a wide range of high-quality products to customers worldwide. With a large workforce and a strong market presence, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. continues to innovate and expand its product offerings to meet the growing demands of the market.
Wuhan Institute of Biological Products Co., Ltd.
Establishment time : Wuhan Institute of Biological Products Co., Ltd. was established in 1967.
website : http://www.whbp.com.cn/.
Main Product : Their main products include vaccines and biological products.
Company Profile
Wuhan Institute of Biological Products Co., Ltd. is a leading manufacturer in the field of biological products and vaccines.
Yisheng Biopharma Co., Ltd.
Establishment time : 2009
website : www.yishengbio.com
Main Product : Vaccines, monoclonal antibodies, diagnostic reagents
Company Profile
Yisheng Biopharma Co., Ltd. is dedicated to developing and producing high-quality biopharmaceutical products to address unmet medical needs. With a focus on innovation and research, the company aims to improve global health outcomes and make a positive impact on society.
Beijing Tiantan Biological Products Co., Ltd.
Establishment time : 1992
website : www.btbp.com.cn
Main Product : Vaccines, blood products, and diagnostic reagents
Company Profile
Beijing Tiantan Biological Products Co., Ltd. is a renowned biopharmaceutical company specializing in the research, development, and production of vaccines, blood products, and diagnostic reagents. Established in 1992, the company has grown to become a key player in the healthcare industry, with a wide range of products distributed in China, Asia, Africa, and Latin America. With over 1,000 employees, the company is known for its high-quality products and commitment to innovation.
Liaoning Chengda Biotechnology Co., Ltd.
Establishment time : 2006
website : www.lnchengda.com
Main Product : Probiotics, enzymes, feed additives
Company Profile
Liaoning Chengda Biotechnology Co., Ltd. is a leading manufacturer of probiotics, enzymes, and feed additives. Established in 2006, the company has grown to become a key player in the industry, serving markets in China, Southeast Asia, and the Middle East. With a medium-sized company size, Chengda Biotechnology faces stiff competition in the market, but maintains a strong presence domestically. Visit their website at www.lnchengda.com for more information.
Chengdu Institute of Biological Products Co., Ltd.
Establishment time : Chengdu Institute of Biological Products Co., Ltd. was founded in 1967.
website :
Main Product : With a large company size, Chengdu Institute of Biological Products Co., Ltd. has a strong presence in both domestic and international markets.
Company Profile
Chengdu Institute of Biological Products Co., Ltd. continues to be a trusted provider of vaccines and biological products worldwide.
Sinovac Biotech Co., Ltd.
Establishment time : Sinovac Biotech Co., Ltd. is a leading biopharmaceutical company based in China.
website :
Main Product : Sinovac has a strong focus on research and development, with a team of scientists dedicated to advancing vaccine technology.
Company Profile
Sinovac continues to innovate and collaborate with partners to address emerging infectious diseases and global health challenges.
